Best Countries for Cannabis Business

The cannabis business is one of the most complex and fast-moving sectors in international commerce. Choosing the right jurisdiction determines not only whether your operation is legal, but also how much capital you need, how quickly you can launch, and what tax burden you will carry. This guide compares the leading countries for cannabis business across licensing frameworks, regulatory requirements, tax treatment, costs, and practical risks - giving founders and investors a clear basis for decision-making.

Cannabis regulation is entirely jurisdiction-specific. A structure that is fully compliant in one country can expose founders to criminal liability in another. Unlike most industries, there is no international framework governing cannabis commerce, which means each country sets its own rules on cultivation, processing, distribution, retail, and export.

The practical consequences are significant. Banking access, insurance, cross-border payments, and investor appetite all depend on the regulatory status of cannabis in the chosen jurisdiction. A non-obvious requirement in many markets is that even where cannabis is legal at the national level, municipal or regional authorities may impose additional restrictions on where and how a business can operate.

Foreign founders frequently underestimate the compliance burden. Licensing timelines can run from a few months to several years. Capital requirements vary from modest to substantial. And in several jurisdictions, the regulatory framework has changed materially in recent years, meaning that advice based on older information can be dangerously out of date.

The jurisdictions covered in this guide - Canada, Germany, the Netherlands, Malta, Uruguay, Thailand, and the United States - represent the current range of viable options for internationally mobile cannabis entrepreneurs. Each has distinct advantages and trade-offs.

Canada was the first major economy to legalise cannabis for adult recreational use at the federal level, under the Cannabis Act. This gives it a significant advantage: a stable, well-tested regulatory framework with established banking relationships, a functioning capital market for cannabis companies, and a body of case law and regulatory guidance that reduces legal uncertainty.

Licensing is administered by Health Canada, the federal regulator. Licence categories cover cultivation, processing, sale, analytical testing, and research. Each category has distinct requirements for physical security, record-keeping, personnel background checks, and quality control. The application process is detailed and document-intensive, and timelines from submission to approval have historically ranged from several months to over a year, depending on the category and the completeness of the application.

In practice, founders should consider that the Canadian market has become highly competitive. Early entrants benefited from limited competition; the current landscape includes hundreds of licensed producers. Margins in cultivation have compressed significantly, and many operators have shifted focus toward value-added products, branded retail, and export-oriented medical cannabis.

The tax treatment of cannabis businesses in Canada is broadly similar to other industries at the corporate level, but there are sector-specific excise duties that apply to cannabis products. Provincial sales taxes also apply. The combined tax burden is meaningful and must be modelled carefully in any business plan.

A common mistake among foreign investors is assuming that a Canadian licence automatically enables export. Canada does permit cannabis exports for medical and scientific purposes under international treaty obligations, but the process requires separate permits and is subject to the import rules of the destination country. Many founders discover this limitation only after committing capital.

Germany';s recent legislative changes have made it one of the most closely watched jurisdictions in Europe for cannabis business. The framework distinguishes between social clubs, which are permitted to cultivate and distribute cannabis to members on a non-commercial basis, and a separate commercial supply chain for medical cannabis, which is subject to pharmaceutical-grade regulation.

The medical cannabis market in Germany is regulated under the Narcotics Act and associated pharmaceutical legislation. Cultivation for medical purposes requires a licence from the Federal Institute for Drugs and Medical Devices (BfArM). Germany has historically imported the majority of its medical cannabis, creating significant opportunities for licensed producers in other jurisdictions who can meet German quality standards - primarily EU-GMP (Good Manufacturing Practice) certification.

For founders considering Germany as a base for cannabis business, the key practical consideration is the distinction between the social club model and the commercial medical supply chain. The social club framework is non-commercial by design and does not support a scalable business. The commercial opportunity lies in medical cannabis, either through domestic cultivation (highly regulated, capital-intensive) or through import and distribution (requiring pharmaceutical wholesale licences and EU-GMP-certified supply).

Germany';s corporate tax environment is well-established, with a combined effective rate that includes corporate income tax and trade tax. Cannabis businesses operating in the pharmaceutical supply chain are treated as pharmaceutical companies for tax purposes, which has both advantages and compliance obligations.

A non-obvious requirement is that EU-GMP certification for cannabis cultivation is a multi-year process. Founders who plan to supply the German market from a third country must factor in the certification timeline before projecting revenue. We can help structure the setup correctly the first time - contact info@vlolawfirm.com for a consultation.

The Netherlands operates under a policy of tolerance - gedoogbeleid - that has historically permitted cannabis retail through licensed coffee shops while cultivation remained technically illegal. A pilot programme for regulated cannabis cultivation has been introduced to address this contradiction, but it is limited in geographic scope and the number of licensed growers.

For international cannabis entrepreneurs, the Netherlands presents a nuanced picture. The coffee shop model is not available to foreign investors in any straightforward sense: licences are municipal, tightly controlled, and not transferable. The regulated cultivation pilot is restricted to approved participants and is not open to new entrants outside the pilot framework.

Where the Netherlands does offer genuine opportunity is in cannabis research, hemp-derived products, and the broader cannabis supply chain - including equipment, technology, and professional services. The Dutch regulatory environment for hemp (cannabis with low THC content) is aligned with EU rules, and the Netherlands has a strong infrastructure for agricultural and pharmaceutical logistics.

The practical scenario for a foreign founder is therefore more likely to involve a B2B or technology play than a direct cultivation or retail licence. Companies providing genetics, growing technology, compliance software, or professional services to the cannabis sector can operate in the Netherlands with relatively few sector-specific restrictions, subject to standard Dutch corporate and commercial law.

Malta became the first European Union member state to legalise cannabis for personal adult use, under the Authority for the Responsible Use of Cannabis Act. The framework permits personal cultivation and the formation of non-profit cannabis associations. However, the commercial retail of cannabis for adult use remains prohibited.

For cannabis business purposes, Malta';s significance lies primarily in its medical cannabis sector. The Malta Medicines Authority regulates medical cannabis cultivation and export under a framework that aligns with EU pharmaceutical standards. Malta has positioned itself as a hub for medical cannabis production and export, with a relatively streamlined licensing process compared to some larger EU jurisdictions.

The Maltese corporate tax system offers a refund mechanism that can reduce the effective corporate tax rate substantially for qualifying companies. This makes Malta attractive for holding and operating structures in the cannabis sector, provided the underlying business activities are genuinely conducted in Malta.

A common mistake is treating Malta purely as a tax structure without substance. Maltese authorities require genuine economic activity - staff, management, and operations - to support the tax treatment. Founders who establish a shell entity without real substance risk both tax challenges and regulatory scrutiny.

Uruguay was the first country in the world to legalise and regulate cannabis for adult use at the national level, under Law 19.172. The framework is administered by the Institute for the Regulation and Control of Cannabis (IRCCA) and covers cultivation, processing, distribution, and retail through pharmacies.

The Uruguayan model is state-centric. The government controls pricing and distribution, which limits the commercial upside for private operators compared to more market-oriented jurisdictions. However, Uruguay does permit licensed private cultivation and processing for export, and this is where the primary opportunity for international cannabis businesses lies.

Uruguay has signed bilateral agreements with several countries to facilitate medical cannabis exports. The regulatory environment is stable and the licensing process, while detailed, is well-documented. Costs of production in Uruguay are generally lower than in Western Europe or North America, which can support competitive export pricing.

The practical scenario for a foreign founder is typically a cultivation and export operation, supplying medical cannabis to European or other regulated markets. The key risks are currency exposure, the relatively small domestic market, and the need to navigate both Uruguayan export regulation and the import rules of the destination country simultaneously.

Thailand';s approach to cannabis has shifted materially in recent years. Cannabis was removed from the narcotics list, creating a window for commercial activity in cultivation, processing, and retail. The regulatory framework is still evolving, and founders should treat current rules as subject to further change.

The opportunity in Thailand is significant. The country has a strong agricultural base, a growing wellness and tourism sector, and a government that has actively encouraged cannabis-related investment. Licences for cultivation, processing, and retail are available to qualifying entities, including those with foreign participation, though restrictions on foreign ownership in certain business categories apply under Thai law.

A non-obvious requirement is that Thai law imposes foreign business restrictions that affect the structure of any cannabis venture. Foreign founders typically need to work within a joint venture or other approved structure rather than operating a wholly foreign-owned entity in most cannabis-related categories. Legal structuring is therefore critical from the outset.

The cost of establishing a cannabis business in Thailand is generally lower than in European or North American markets. However, the regulatory uncertainty - given the pace of legislative change - means that founders must build flexibility into their business models and maintain close monitoring of regulatory developments.

The United States presents the largest commercial cannabis market in the world, but also the most structurally complex regulatory environment. Cannabis remains a Schedule I controlled substance under federal law, while a majority of states have legalised it for medical or adult recreational use, or both.

The consequence of this federal-state conflict is significant for business operations. Cannabis businesses in the United States cannot access federal banking services in the same way as other industries, cannot take standard business deductions under the federal tax code (under the provision known as Section 280E of the Internal Revenue Code), and cannot move cannabis products across state lines even between two legal states.

Each state operates its own licensing regime. Requirements, fees, timelines, and licence categories vary substantially. Some states have social equity provisions that affect who can obtain a licence. Others have caps on the number of licences available, creating a competitive application process. Timelines from application to operation can range from several months to several years depending on the state and licence type.

For foreign founders, the additional complexity is that cannabis business licences in most states require the applicant or a controlling party to be a US resident or citizen. Foreign investment is possible through carefully structured arrangements, but direct ownership of a state cannabis licence by a foreign national is typically not permitted. Legal structuring is essential, and the cost of getting it wrong - including potential licence revocation - is high.

In practice, founders should consider that the US market rewards scale and brand, but the capital requirements are substantial and the regulatory burden is ongoing. Many international investors participate through holding companies, debt instruments, or ancillary businesses (technology, equipment, real estate) rather than direct licence ownership.

Contact info@vlolawfirm.com to discuss how to structure international cannabis investment correctly before committing capital.

When selecting a jurisdiction for cannabis business, the relevant dimensions are: legal status of the activity, licensing accessibility for foreign founders, regulatory stability, tax treatment, cost of compliance, and market size or export potential.

Canada offers the most mature framework and the largest domestic market outside the United States, with genuine export potential for medical cannabis. Germany offers access to the EU';s largest medical cannabis market but requires EU-GMP certification and significant capital. Malta offers a favourable tax environment and EU market access for medical cannabis, with genuine substance requirements. The Netherlands offers limited direct cannabis business opportunity but a strong environment for ancillary businesses. Uruguay offers low-cost production and export potential with a stable regulatory framework. Thailand offers significant opportunity at lower cost but with regulatory uncertainty and foreign ownership restrictions. The United States offers the world';s largest market but with federal complexity, state-by-state variation, and significant barriers for foreign founders.

A common mistake is selecting a jurisdiction based on a single factor - typically tax rate or ease of formation - without modelling the full compliance cost, licensing timeline, and market access picture. The best jurisdiction for a cannabis business depends on the specific activity, the founder';s nationality and resources, and the target market.

What is the most accessible jurisdiction for a foreign founder entering the cannabis business?

Canada and Malta are generally the most accessible for foreign founders, though neither is without complexity. Canada has a well-documented federal licensing process administered by Health Canada, and foreign nationals can hold shares in a licensed entity, though background checks and residency requirements for key personnel apply. Malta';s medical cannabis licensing framework is relatively streamlined by EU standards, and the corporate structure can accommodate foreign ownership with appropriate substance. In both cases, professional legal and regulatory advice is essential before submitting any application. The cost of a rejected application - in both time and fees - is significant.

How long does it typically take to obtain a cannabis business licence, and what does it cost?

Timelines vary enormously by jurisdiction and licence type. In Canada, the process from application to licence approval has historically taken from several months to over a year for cultivation licences. In Germany, EU-GMP certification alone can take two or more years. In Thailand, timelines are shorter but regulatory changes can affect the process mid-application. Costs are similarly variable: state and regulatory fees are one component, but professional fees for legal, compliance, and quality assurance support often represent the larger share of pre-licence expenditure. Founders should budget for professional fees starting from the low tens of thousands of EUR for simpler applications, rising substantially for complex cultivation or pharmaceutical-grade licences.

Should a cannabis business be structured as a holding company in one jurisdiction with operations in another?

This is a common and often sensible approach, but it requires careful legal analysis. A holding structure can offer tax efficiency, investor flexibility, and separation of liability. However, cannabis-specific rules in many jurisdictions restrict who can hold a licence or a controlling interest in a licensee, and some regulators require disclosure and approval of all beneficial owners regardless of where they are incorporated. Substance requirements in holding jurisdictions - particularly within the EU - mean that a purely paper structure is unlikely to withstand scrutiny. The structure must be designed around the specific regulatory requirements of the operating jurisdiction, not the other way around.

The cannabis business offers genuine commercial opportunity across multiple jurisdictions, but the regulatory complexity is real and the cost of structural errors is high. Canada, Germany, Malta, Uruguay, Thailand, and the United States each offer distinct advantages depending on the activity, the founder';s profile, and the target market. No single jurisdiction is optimal for every cannabis business, and the right choice requires a detailed analysis of licensing, tax, costs, and market access.

VLO Law Firms advises international clients on cannabis business across multiple jurisdictions. We can assist with jurisdiction selection, corporate structuring, licence applications, regulatory compliance, and cross-border investment arrangements. To request a consultation, contact: info@vlolawfirm.com